Athira Pharma reports FY23 EPS ($3.09), consensus ($3.33)

“We’ve made important progress in our pursuit to advance potential new treatment options for neurodegenerative diseases. Importantly, in January, we announced completing enrollment in our Phase 2/3 LIFT-AD clinical trial, which is evaluating fosgonimeton in approximately 315 patients with mild-to-moderate Alzheimer’s disease,” stated Mark Litton, Ph.D., President and Chief Executive Officer of Athira. “We are encouraged by results shown to date, which we believe support fosgonimeton’s potential to deliver a first-in-class therapy to Alzheimer’s disease patients and expect to report topline data from LIFT-AD in the second half of 2024. Additionally, we are excited to advance ATH-1105 for the potential treatment of ALS and remain on-track to initiate the first-in-human study in the first half of 2024. We ended 2023 with a strong balance sheet that we believe will support the ongoing advancement of our pipeline, including fosgonimeton and ATH-1105, through key inflection points.”